Navigation Links
Genzyme Provides Update on Myozyme(R) Manufacturing
Date:4/21/2008

Will Host Conference Call Today at 5:00 p.m.

CAMBRIDGE, Mass., April 21 /PRNewswire-FirstCall/ -- Genzyme Corporation (Nasdaq: GENZ) announced today that the FDA has informed the company of its opinion that Myozyme(R) (alglucosidase alfa) produced at the 160L bioreactor scale and Myozyme produced at the 2000L scale should be classified as two different products because of differences in the carbohydrate structures of the molecules. Currently, Genzyme has U.S. approval to sell Myozyme manufactured at the 160L scale, and the company has been seeking clearance from the FDA for Myozyme produced at the 2000L scale. Production at this larger scale has already been approved in more than 40 countries.

Based on the global clinical experience of nearly 900 patients of all ages currently receiving Myozyme produced at the larger scale, including patients who participated in the Late-Onset Treatment Study (LOTS), Genzyme believes that Myozyme produced at both the 160L and 2000L scales is clinically effective and safe. Myozyme is the only treatment for Pompe disease -- a severe, progressively debilitating and life-threatening inherited disorder affecting a very small number of people throughout the world.

The FDA will require Genzyme to submit a separate biologics license application (BLA) to gain approval for Myozyme produced at the 2000L scale. The agency proposed that Genzyme initiate a rolling BLA review process by submitting results from the LOTS study. Genzyme expects the FDA to give the BLA priority review and to act on the application by the end of this year. The LOTS study, which met its co-primary efficacy endpoints, was undertaken to evaluate the safety and efficacy of Myozyme in juvenile and adult patients w
'/>"/>

SOURCE Genzyme Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Genzyme Withdraws Bioenvisions European Filing of Evoltra(R) in Elderly AML Patients
2. Genzyme Launches Renvela(R) in the U.S. for Dialysis Patients
3. Genzyme and Isis Announce Hart-Scott-Rodino Approval of Collaboration
4. Genzyme and Isis Announce Strategic Alliance Including Exclusive Worldwide License of Mipomersen
5. BioMarin and Genzyme Restructure Aldurazyme 50/50 Joint Venture
6. Genzyme Receives European CE Mark for Single-Treatment Synvisc-One(TM)
7. Genzyme Announces FDA Approval of Thyrogen(R) for Use in Thyroid Cancer Ablation
8. Genzyme Study of Myozyme(R) for Late-Onset Pompe Patients Meets Co-Primary Efficacy Endpoints
9. Genzyme and Sunway to Collaborate on Gene Therapy Program in China
10. BioVex Appoints Genzyme Executive, Jan van Heek, as Chairman of the Board of Directors
11. Genzyme Launches Cholestagel(R) in Europe
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2015)... , 27 avril 2015 ... spécialisée dans le développement d,une nouvelle ... les infections bactériennes polypharmacorésistantes potentiellement mortelles, ... données prouvant les promesses de son ... la lutte contre la résistance aux ...
(Date:4/27/2015)... 2015 SynGen Inc., a company that focuses ... harvest stem and progenitor cells from umbilical cord blood, ... that it has added three new members to its ... Business Units focus on product commercialization. ... Vice President and Chief Financial Officer.  Chuck was most ...
(Date:4/27/2015)... Texas (PRWEB) April 27, 2015 ... for use in applications such as animal waste ... and oil reduction in wastewater treatment plants and ... an exhibitor at the Texas Commission on Environmental ... 5-6 in Austin, Texas. , The company will ...
(Date:4/27/2015)... Diasome Pharmaceuticals, Inc. (“Diasome”) has announced ... Center (“Joslin”) to collaborate on the design of ... Directed Vesicle (“HDV”) targeting system for insulin in ... in Boston, Massachusetts, Joslin is the world's leading ... to the prevention, treatment and cure of diabetes. ...
Breaking Biology Technology:TAXIS Pharmaceuticals démontre la puissance clinique du TXA709 dans la lutte contre la résistance aux antibiotiques 2TAXIS Pharmaceuticals démontre la puissance clinique du TXA709 dans la lutte contre la résistance aux antibiotiques 3TAXIS Pharmaceuticals démontre la puissance clinique du TXA709 dans la lutte contre la résistance aux antibiotiques 4TAXIS Pharmaceuticals démontre la puissance clinique du TXA709 dans la lutte contre la résistance aux antibiotiques 5TAXIS Pharmaceuticals démontre la puissance clinique du TXA709 dans la lutte contre la résistance aux antibiotiques 6SynGen Inc. Expands Its Management Team 2DryLet to Showcase Multiple Products at Texas Commission on Environmental Quality Trade Fair and Conference May 5-6 in Austin, Texas 2Diasome Pharmaceuticals Announces Clinical Trial Design Collaboration 2
... PRINCETON, N.J., July 7 Medarex, Inc.,(Nasdaq: MEDX ... to,listen to a live webcast of its 2008 R&D ... 2008 at 8:00 a.m. Eastern Time and is expected ... will,provide an overview of the company,s strategy, progress and ...
... 7 The winners of the Ferring Research,Infertility ... the,European Society for Human Reproduction & Embryology Congress. ... University Medical Centre Utrecht, The,Netherlands and the Universitair ... winning research institutions were selected for their outstanding,proposals ...
... 7, 2008 Senomyx, Inc.,(Nasdaq: SNMX ), ... discover and develop novel flavor ingredients for the ... one-year extension of its,exclusive collaborative research and license ... Cadbury plc, for the discovery and commercialization of,new ...
Cached Biology Technology:Medarex Announces July 10 Live Webcast of R&D Day Event 2Ferring Research Infertility and Gynaecology GrAnt (FRIGGA) 2008 Winners Announced 2Ferring Research Infertility and Gynaecology GrAnt (FRIGGA) 2008 Winners Announced 3SENOMYX ANNOUNCES EXTENSION OF DISCOVERY AND DEVELOPMENT COLLABORATION WITH CADBURY PLC 2SENOMYX ANNOUNCES EXTENSION OF DISCOVERY AND DEVELOPMENT COLLABORATION WITH CADBURY PLC 3
(Date:4/14/2015)... April 14, 2015 NXT-ID, Inc. (NASDAQ: ... company focused on the growing mobile commerce market, announces ... the 2015 New York Design Awards under the category  ... York City Design Awards are part of a global ... 2,500 ratings from the marketplace, industry and judging panel. ...
(Date:4/13/2015)... -- higi, a leading cloud-based consumer engagement platform that provides ... their communities around health and wellness, announced today the ... ... convenient vehicle to receive validated health information from consumers. ... API will allow higi,s trusted partners, on a user ...
(Date:4/9/2015)... SAN JOSE, Calif. , April 9, 2015 /PRNewswire/ ... of human interface solutions, announced today that it will ... 2015 on Thursday, April 23, 2015, after the close ... call for analysts and investors at 2:00 p.m. PT ... information.    To participate on the live ...
Breaking Biology News(10 mins):NXT-ID's Wocket Smart Wallet Nominated for 2015 New York Design Awards in 'Product Design- Technology' 2NXT-ID's Wocket Smart Wallet Nominated for 2015 New York Design Awards in 'Product Design- Technology' 3higi Launches Seamless Access to HIPAA-Compliant Health Outcomes and Activity Data 2higi Launches Seamless Access to HIPAA-Compliant Health Outcomes and Activity Data 3Synaptics to Report Third Quarter Results on April 23 2
... parasites, roads as weed highways, and chemical warfare between alien and ... covered in NeoBiota a new open-access, peer-reviewed, ... by Pensoft Publishers continuing the former NeoBiota ... Ingolf Khn from the Helmholtz Centre for Environmental Research ...
... NYU Langone Medical Center,s Departments of Orthopaedic Surgery and ... to detect subtle changes in joint cartilage microstructure ... markers of early osteoarthritis (OA). By using these techniques ... shift the management of the disease from eventual joint ...
... of Toronto, The Hospital for Sick Children (SickKids), St. ... identified a new treatment target for a virus that ... common colds. The virus, called human respiratory syncytial virus ... of infants and children under two years of age; ...
Cached Biology News:Open minded and open access: NeoBiota, a new publishing platform for invasion biologists 2Open minded and open access: NeoBiota, a new publishing platform for invasion biologists 3NYU Langone experts find MRI techniques can detect early osteoarthritis 2Researchers map pathway of infection for a common, potentially life-threatening respiratory virus 2
... This CLS number is a new ... Cornings product number. If showing no ... old Sigma-Aldrich number (E6152) or contact ... Dim: H diam. 11.25 ...
... This gradient system uses three Adept ... each providing a flow rate in one ... UV/Visible ultra-fast scanning detector, provides added flexibility. ... alternative to a photodiode array detection and ...
A convenience pack containing one each of the most popular sizes of Cat. No. 4980 flask. Designed for the low volume user, a case contains one each of five sizes: 50mL, 125mL, 250mL, 500mL, and 1L....
... The excellent isocratic refractive index chromatography system, ... CE 4700. Data processing is provided ... delivery is by the high pressure CE 4100 ... can be supplied. The system can ...
Biology Products: